Aurinia Pharmaceuticals. has filed a patent for methods to enhance the effectiveness of voclosporin in treating proteinuric kidney diseases while minimizing side effects like calcineurin inhibitor nephrotoxicity. The patent includes a method to reduce nephrotoxicity in lupus nephritis by administering a specific dosage of voclosporin and monitoring renal function. GlobalData’s report on Aurinia Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Aurinia Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Aurinia Pharmaceuticals, Cyclosporin derivatives was a key innovation area identified from patents. Aurinia Pharmaceuticals's grant share as of January 2024 was 50%. Grant share is based on the ratio of number of grants to total number of patents.

Method to reduce nephrotoxicity in lupus nephritis treatment

Source: United States Patent and Trademark Office (USPTO). Credit: Aurinia Pharmaceuticals Inc

A patent application (Publication Number: US20230381271A1) discloses a method to reduce chronic calcineurin inhibitor nephrotoxicity in the treatment of lupus nephritis. The method involves administering a specific daily dosage of voclosporin to a subject diagnosed with lupus nephritis over a projected treatment period of at least 100 weeks. The dosage is adjusted based on the assessment of the subject's estimated Glomerular Filtration Rate (eGFR) at different time points during the treatment. If the eGFR decreases by a certain percentage, the dosage is reduced, while if it remains stable, the dosage is continued. The method also includes various assessments such as renal biopsies to monitor interstitial fibrosis, tubular atrophy, glomerular injury, and other factors that may impact the treatment efficacy.

Furthermore, the method involves identifying suitable subjects for the treatment based on specific criteria related to urine protein creatinine ratio, eGFR, and other factors. The patent application also includes provisions for adjusting the dosage based on the presence of certain conditions such as juxtaglomerular apparatus hyperplasia, tubular microcalcifications, and alterations in renal vascular resistance. Additionally, the method incorporates monitoring of electrolyte levels, lipid profiles, and other parameters to ensure the treatment does not result in adverse effects. Overall, the method aims to provide a personalized approach to managing lupus nephritis while minimizing the risk of nephrotoxicity associated with calcineurin inhibitors over an extended treatment period of at least 100 weeks, with the second time point for assessment typically set around 50-60 weeks after initiating voclosporin administration.

To know more about GlobalData’s detailed insights on Aurinia Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies